BidaskClub downgraded shares of Sarepta Therapeutics (NASDAQ:SRPT) from a buy rating to a hold rating in a research report report published on Thursday.

SRPT has been the topic of several other reports. HC Wainwright upped their price objective on shares of Sarepta Therapeutics from $96.00 to $267.00 and gave the stock a buy rating in a report on Tuesday, June 19th. Needham & Company LLC upped their price objective on shares of Sarepta Therapeutics from $109.00 to $204.00 and gave the stock a buy rating in a report on Wednesday, June 20th. Leerink Swann restated an outperform rating on shares of Sarepta Therapeutics in a report on Wednesday, June 20th. Royal Bank of Canada upped their price objective on shares of Sarepta Therapeutics to $189.00 and gave the stock an outperform rating in a report on Wednesday, June 20th. Finally, Piper Jaffray Companies restated an overweight rating and set a $168.00 price objective on shares of Sarepta Therapeutics in a report on Wednesday, June 20th. Four investment analysts have rated the stock with a hold rating, twenty-one have issued a buy rating and one has issued a strong buy rating to the company. The stock has an average rating of Buy and a consensus price target of $147.98.

NASDAQ SRPT traded up $0.15 on Thursday, hitting $129.73. 15,641 shares of the company were exchanged, compared to its average volume of 1,550,792. The firm has a market cap of $8.61 billion, a PE ratio of -78.51 and a beta of 1.34. Sarepta Therapeutics has a 12 month low of $35.26 and a 12 month high of $176.50. The company has a quick ratio of 9.89, a current ratio of 10.88 and a debt-to-equity ratio of 0.62.

Sarepta Therapeutics (NASDAQ:SRPT) last issued its earnings results on Wednesday, August 8th. The biotechnology company reported ($1.67) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.68) by ($0.99). The company had revenue of $73.53 million for the quarter, compared to the consensus estimate of $71.53 million. Sarepta Therapeutics had a negative return on equity of 19.34% and a negative net margin of 89.64%. The firm’s revenue was up 110.0% compared to the same quarter last year. During the same period in the prior year, the company earned ($0.48) earnings per share. equities analysts predict that Sarepta Therapeutics will post -2.09 earnings per share for the current year.

In other news, Director Richard Barry sold 75,000 shares of the stock in a transaction dated Wednesday, June 27th. The shares were sold at an average price of $130.34, for a total value of $9,775,500.00. Following the completion of the sale, the director now owns 3,170,432 shares in the company, valued at $413,234,106.88. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, SVP Alexander Cumbo sold 33,782 shares of the stock in a transaction dated Monday, July 9th. The shares were sold at an average price of $137.32, for a total transaction of $4,638,944.24. Following the completion of the sale, the senior vice president now owns 40,690 shares of the company’s stock, valued at approximately $5,587,550.80. The disclosure for this sale can be found here. In the last quarter, insiders sold 158,782 shares of company stock valued at $21,237,444. 7.90% of the stock is currently owned by corporate insiders.

Several hedge funds have recently made changes to their positions in the company. Xact Kapitalforvaltning AB raised its holdings in shares of Sarepta Therapeutics by 5.7% in the second quarter. Xact Kapitalforvaltning AB now owns 9,202 shares of the biotechnology company’s stock valued at $1,216,000 after purchasing an additional 500 shares during the last quarter. Principal Financial Group Inc. raised its holdings in shares of Sarepta Therapeutics by 2.7% in the first quarter. Principal Financial Group Inc. now owns 19,946 shares of the biotechnology company’s stock valued at $1,478,000 after purchasing an additional 530 shares during the last quarter. Fuller & Thaler Asset Management Inc. raised its holdings in shares of Sarepta Therapeutics by 0.5% in the second quarter. Fuller & Thaler Asset Management Inc. now owns 145,854 shares of the biotechnology company’s stock valued at $19,279,000 after purchasing an additional 709 shares during the last quarter. SeaCrest Wealth Management LLC raised its holdings in shares of Sarepta Therapeutics by 59.0% in the second quarter. SeaCrest Wealth Management LLC now owns 2,326 shares of the biotechnology company’s stock valued at $307,000 after purchasing an additional 863 shares during the last quarter. Finally, Commonwealth Equity Services LLC raised its holdings in shares of Sarepta Therapeutics by 11.0% in the second quarter. Commonwealth Equity Services LLC now owns 8,989 shares of the biotechnology company’s stock valued at $1,188,000 after purchasing an additional 892 shares during the last quarter. Institutional investors own 85.00% of the company’s stock.

About Sarepta Therapeutics

Sarepta Therapeutics, Inc focuses on the discovery and development of RNA-based therapeutics, gene therapy, and other genetic medicine approaches for the treatment of rare neuromuscular diseases. The company offers EXONDYS 51, a disease-modifying therapy for the treatment of duchenne muscular dystrophy (DMD), which is a rare genetic muscle-wasting disease caused by the absence of dystrophin.

Read More: Google Finance Portfolio

Analyst Recommendations for Sarepta Therapeutics (NASDAQ:SRPT)

Receive News & Ratings for Sarepta Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sarepta Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.